Christian Shull, MD
Hematology & Oncology · Idaho Falls, IDNPI 1396899134
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $102,643 of the $149,970 with a category attached, or 68.4%. 60 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 43.2% of the total. Reporting peaked in 2022 at $58,928 and has fallen 68.9% since, to $18,300 in 2025. Among hematology & oncology clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 963 payments — averaging $155.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$65K
- Sanofi$45K
- Myriad Genetic Laboratories, Inc.$15K
- Gilead$7K
- AstraZeneca$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- plus $13K from 54 others
What the payments were for
- Consulting fees$14,31410%
- Speaking & faculty fees$102,64368%
- Travel & lodging$13,8269%
- Food & beverage$18,58912%
- Education$5990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$149,970 in reported general payments places this provider in the 90th percentile of 34 hematology & oncology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 64 | $862,273 |
| CalquenceAcalabrutinib Maleate | 42 | $517,008 |
| TasignaNilotinib Hcl | 16 | $396,903 |
| VerzenioAbemaciclib | 25 | $372,240 |
| RevlimidLenalidomide | 22 | $318,610 |
| ErleadaApalutamide | 15 | $258,734 |
| VenclextaVenetoclax | 13 | $181,003 |
| BrukinsaZanubrutinib | 12 | $177,899 |
| Abiraterone Acetate | 86 | $89,261 |
| EliquisApixaban | 96 | $63,287 |
| Ondansetron Hcl | 79 | $14,528 |
| Letrozole | 173 | $2,651 |
| ValacyclovirValacyclovir Hcl | 60 | $2,100 |
| Fentanyl | 14 | $1,634 |
| Tamoxifen Citrate | 30 | $1,366 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $3,901 | $517,00842 claims |
| NovartisTasigna | $798 | $396,90316 claims |
| Lilly USA, LLCVerzenio | $154 | $372,24025 claims |
| Bristol Myers SquibbRevlimid | $293 | $318,61022 claims |
| Johnson & JohnsonErleada | $813 | $258,73415 claims |
| AbbVieVenclexta | $470 | $181,00313 claims |
| Beigene USA, Inc.Brukinsa | $53 | $177,89912 claims |
| PfizerEliquis | $869 | $63,28796 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 34 hematology & oncology providers in Idaho.
Other hematology & oncology in Idaho Falls
- Nathan AdamsIdaho Falls$16K
- Maria Cervantes FullmerIdaho Falls$9K
- Danko MartincicPost Falls$1.1M
- Bobby ChawlaCaldwell$1M
- Dane DicksonRexburg$21K
- Ian QureshiNampa$18K
- Andrew KominskyCoeur D Alene$13K
- David BartelsCoeur D Alene$11K
- Sri Harsha TellaMeridian$8K
- Rajeev RajendraMoscow$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.